Also trades as: SLXN (NASDAQ) · $vol 0M
SLXNW NASDAQ
Silexion Therapeutics Ltd.
1W: -15.9%
1M: -47.8%
3M: -68.6%
YTD: -72.3%
1Y: -82.0%
$0.02
+0.01 (+71.31%)
Weekly Expected Move ±107.6%
$-0
$-0
$0
$0
$0
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.0M
52W Range0.0108-0.032
Volume2,000
Avg Volume65,362
Beta-0.29
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOIlan Hadar
Employees11
SectorHealthcare
IndustryBiotechnology
IPO Date2024-08-16
Websitesilexion.com
The Goldyne Savad Institute of Gene Therapy
Jerusalem 9112001
IL
Jerusalem 9112001
IL
972 2 674 3430
About Silexion Therapeutics Ltd.
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Shirvan Mitchell | S-Sale | 22,818 | $1.36 | 2026-03-26 |
| Noy Shlomo | A-Award | 9,091 | — | 2026-02-20 |
| Noy Shlomo | A-Award | 10,685 | $1.65 | 2026-02-20 |
| Alon Ruth | A-Award | 9,091 | — | 2026-02-20 |
| Shirvan Mitchell | A-Award | 49,726 | — | 2026-02-20 |